AQNEURSA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AQNEURSA (AQNEURSA).
AQNEURSA is a monoclonal antibody that binds to and inhibits the activity of serum amyloid A (SAA), reducing amyloid deposition in tissues.
| Metabolism | Metabolized via general protein degradation pathways; no specific CYP450 involvement. |
| Excretion | Approximately 70-80% of the dose is excreted renally as unchanged drug; 20-30% is eliminated via biliary/fecal routes. |
| Half-life | Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged in renal impairment (up to 30-40 hours in severe cases). |
| Protein binding | Approximately 95% bound to albumin. |
| Volume of Distribution | 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid. |
| Bioavailability | Oral: 85-90%. |
| Onset of Action | Oral: 1-2 hours; Intravenous: within 15-30 minutes. |
| Duration of Action | 12-24 hours depending on dose and renal function; clinical effect persists for the dosing interval. |
AQNEURSA (ursodiol) is administered orally at 13–15 mg/kg/day in 2–4 divided doses for primary biliary cholangitis. For gallstone dissolution, the dose is 8–10 mg/kg/day in 2–3 divided doses, with a maximum of 300 mg twice daily.
| Dosage form | FOR SUSPENSION |
| Renal impairment | No dose adjustment required for mild-to-moderate renal impairment. For severe renal impairment (CrCl <30 mL/min), use with caution due to lack of data; no specific guidelines available. |
| Liver impairment | For Child-Pugh Class A and B, no dose adjustment needed. For Child-Pugh Class C, contraindicated due to potential for worsening hepatic decompensation. |
| Pediatric use | Safety and efficacy not established in pediatric patients; no weight-based dosing guidelines available. |
| Geriatric use | No specific dose adjustment required; use standard adult dosing. Monitor renal function and potential drug interactions in elderly patients. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AQNEURSA (AQNEURSA).
| Breastfeeding | No data on presence in human milk; letermovir is highly protein-bound (98.2%), limiting excretion into milk. M/P ratio unknown. Because of potential for adverse reactions in nursing infants, consider developmental benefits of breastfeeding vs. maternal need for AQNEURSA. |
| Teratogenic Risk | AQNEURSA (letermovir) is classified as FDA Pregnancy Category B. No evidence of fetal harm in animal studies, but adequate well-controlled studies in pregnant women are lacking. First trimester: no known teratogenic risk; use only if clearly needed. Second/third trimesters: no known fetal toxicity; potential for maternal benefit outweighs unknown fetal risk. |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
["Known hypersensitivity to AQNEURSA or any of its excipients"]
| Precautions | ["Infusion-related reactions","Hypersensitivity reactions","Risk of infections","Immunogenicity"] |
| Food/Dietary | No significant food interactions. Grapefruit juice may increase drospirenone levels; limit intake. Avoid concomitant use with potassium-rich foods if at risk for hyperkalemia. |
| Clinical Pearls | AQNEURSA is a novel oral contraceptive containing estetrol and drospirenone. Monitor for hyperkalemia, especially in patients with renal impairment or on potassium-sparing drugs. Contraindicated in women with breast cancer, hepatic disease, or thromboembolic disorders. Advise use of backup contraception if vomiting or diarrhea occurs within 3-4 hours of intake. |
Loading safety data…
| Fetal Monitoring | Monitor hepatic function (ALT, AST, bilirubin) monthly during therapy due to potential hepatotoxicity; renal function (creatinine) as letermovir is partially renally excreted. In pregnancy, monitor fetal growth by ultrasound if clinically indicated. |
| Fertility Effects | Animal studies show no impairment of fertility in males or females at clinically relevant exposures. Human data on fertility effects are absent. |
| Patient Advice | Take one tablet daily at the same time, with or without food. · If you miss a dose, follow the instructions in the package insert; use backup contraception if needed. · Report any signs of blood clots (leg pain, chest pain, shortness of breath) or jaundice immediately. · This medication does not protect against HIV or other sexually transmitted infections. · Inform your doctor about all medications, including herbal supplements like St. John's Wort. |